The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.

Key Inclusion Criteria:

• Age 18-64 years (both inclusive) at the time of signing informed consent.
• Male or female (sex assigned at birth).
• Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
• Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Key Exclusion Criteria:

• Previous dosing of marketed or non-marketed amylin-agonists (a).

• Any condition, unwillingness or inability which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol (a).

  1. As declared by the participant, reported in the medical records or at the investigator's discretion.

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com